Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 14 04:00PM ET
9.23
Dollar change
+0.34
Percentage change
3.82
%
Index- P/E20.63 EPS (ttm)0.45 Insider Own55.82% Shs Outstand13.82M Perf Week-7.14%
Market Cap127.55M Forward P/E41.95 EPS next Y0.22 Insider Trans0.00% Shs Float6.10M Perf Month-16.01%
Income6.43M PEG- EPS next Q-0.20 Inst Own17.84% Short Float1.90% Perf Quarter77.16%
Sales58.59M P/S2.18 EPS this Y165.22% Inst Trans-3.90% Short Ratio1.99 Perf Half Y126.78%
Book/sh0.05 P/B185.68 EPS next Y-26.67% ROA22.39% Short Interest0.12M Perf Year56.44%
Cash/sh0.23 P/C39.86 EPS next 5Y- ROE376.84% 52W Range3.60 - 11.99 Perf YTD7.70%
Dividend Est.- P/FCF- EPS past 5Y- ROI61.37% 52W High-23.02% Beta0.46
Dividend TTM- Quick Ratio0.75 Sales past 5Y13.78% Gross Margin51.58% 52W Low156.38% ATR (14)0.88
Dividend Ex-Date- Current Ratio0.99 EPS Y/Y TTM165.43% Oper. Margin11.48% RSI (14)43.10 Volatility11.15% 8.40%
Employees210 Debt/Eq1.18 Sales Y/Y TTM19.03% Profit Margin10.97% Recom1.00 Target Price12.00
Option/ShortYes / Yes LT Debt/Eq0.91 EPS Q/Q266.58% Payout- Rel Volume0.40 Prev Close8.89
Sales Surprise32.09% EPS Surprise3700.00% Sales Q/Q41.77% EarningsMar 11 BMO Avg Volume58.06K Price9.23
SMA20-7.91% SMA50-9.67% SMA20049.44% Trades Volume23,382 Change3.82%
Date Action Analyst Rating Change Price Target Change
Sep-12-24Upgrade Craig Hallum Hold → Buy $6
Nov-18-19Initiated The Benchmark Company Speculative Buy
Mar-11-25 03:55PM
Mar-06-25 04:00PM
Feb-18-25 09:00AM
Feb-14-25 03:47PM
Jan-09-25 08:30AM
08:00AM Loading…
Jan-08-25 08:00AM
Dec-11-24 04:00PM
Dec-05-24 04:30PM
Oct-16-24 10:55AM
Oct-09-24 07:00PM
03:05PM
Sep-12-24 08:03AM
Sep-11-24 04:00PM
Sep-09-24 04:00PM
Jul-18-24 09:53PM
04:00PM Loading…
04:00PM
Jul-11-24 04:05PM
Jun-04-24 09:00AM
Mar-19-24 08:28AM
Mar-12-24 04:30PM
Mar-07-24 09:00AM
Mar-06-24 04:35PM
Dec-14-23 08:22AM
Dec-12-23 09:54PM
04:00PM
Dec-04-23 04:30PM
Nov-02-23 08:30AM
Oct-17-23 08:30AM
Sep-13-23 04:00PM
Sep-11-23 04:00PM
08:30AM Loading…
Aug-22-23 08:30AM
Aug-01-23 08:45AM
Jul-24-23 04:00PM
Jul-20-23 04:00PM
Apr-17-23 08:30AM
Apr-05-23 09:50AM
Mar-15-23 03:50PM
Mar-13-23 08:30AM
Dec-16-22 08:48AM
Dec-13-22 04:00PM
Dec-09-22 04:30PM
Sep-08-22 04:00PM
Sep-06-22 04:00PM
Aug-15-22 08:08AM
Jul-23-22 09:57AM
Jul-21-22 04:00PM
Jul-14-22 04:00PM
Jun-13-22 06:30AM
May-31-22 08:30AM
May-03-22 08:30AM
May-02-22 01:16PM
Mar-15-22 04:45PM
Mar-11-22 08:30AM
Mar-07-22 01:10PM
Feb-15-22 08:30AM
Jan-20-22 08:30AM
Jan-04-22 08:30AM
05:07AM
Dec-13-21 04:20PM
Dec-06-21 09:20AM
Nov-05-21 08:24AM
Oct-20-21 10:25AM
Sep-13-21 04:00PM
Sep-06-21 03:00PM
07:09AM
Sep-02-21 04:30PM
Jul-26-21 08:30AM
Jul-22-21 08:00AM
Jul-14-21 08:30AM
Jul-08-21 03:06AM
Jun-15-21 09:00AM
Apr-29-21 03:31AM
Apr-16-21 12:00PM
Mar-16-21 10:52AM
Mar-15-21 02:13AM
Mar-11-21 04:00PM
02:30PM
Mar-05-21 08:30AM
Mar-04-21 12:30PM
Feb-22-21 09:00AM
Jan-29-21 12:24AM
Jan-19-21 09:00AM
Jan-05-21 08:30AM
Dec-15-20 12:22AM
Dec-14-20 04:00PM
Dec-07-20 04:00PM
Nov-16-20 04:40PM
Nov-11-20 09:00AM
Oct-31-20 10:08AM
Sep-16-20 07:27AM
Sep-14-20 04:00PM
Sep-08-20 04:30PM
Jul-30-20 07:21AM
Jul-27-20 04:01PM
Jul-22-20 08:00AM
Jul-15-20 03:55PM
Jun-17-20 09:37AM
May-27-20 07:05AM
Apr-28-20 09:50AM
Apr-27-20 07:20AM
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ACKERMAN JOELDirectorOct 31 '24Option Exercise2.63105,137276,289962,134Nov 01 09:04 AM